Clinical Trials for Uterine Cancer

A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with TP53 wild-type advanced or recurrent endometrial carcinoma (endometrioid, serous, undifferentiated, or carcinosarcoma) who achieved CR/PR after at least 12 weeks of first-line platinum therapy are randomized to maintenance selinexor vs placebo. Selinexor is an oral exportin 1 (XPO1) inhibitor that promotes nuclear retention/reactivation of tumor suppressors; treatment is 60 mg once weekly on a 28-day cycle.

ClinicalTrials.gov ID: NCT05611931

A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent/persistent RAS-pathway–mutant ovarian, fallopian tube, primary peritoneal, or endometrial cancers (KRAS/NRAS/HRAS/BRAF/MEK1/MEK2 activating or NF1 loss), measurable and biopsiable, are randomized to selumetinib (MEK1/2 inhibitor) plus olaparib (PARP inhibitor) versus selumetinib alone; ovarian patients must be platinum-ineligible and endometrial patients should have received or been offered immunotherapy (± lenvatinib). No prior MEK inhibitors or progression on PARP allowed; crossover to the combination is permitted at progression from selumetinib monotherapy.

ClinicalTrials.gov ID: NCT05554328

A Single-Center, Open-Label, Single-Arm, Phase I Study With Dose Expansion Cohort of Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Platinum-sensitive recurrent epithelial ovarian, fallopian tube, primary peritoneal, or endometrial cancer in adult women (PS 0–1) treated with sacituzumab govitecan (Trop-2–directed ADC delivering SN-38, a topoisomerase I inhibitor) combined with fixed-dose cisplatin every 21 days. Separate ovarian and endometrial cohorts with dose-finding followed by expansion to assess response.

ClinicalTrials.gov ID: NCT06040970

A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent mismatch repair–deficient endometrial carcinoma (non-serous, non-carcinosarcoma) after 1–2 prior lines are randomized to nivolumab (PD-1 inhibitor) plus ipilimumab (CTLA-4 inhibitor) versus nivolumab alone, including patients with treated/stable brain metastases and select stable autoimmune disease; prior PD-1/PD-L1 allowed only if part of combination therapy with ≥12-month CR interval. Treatment continues until progression/toxicity/CR with nivolumab maintenance permitted after CR.

ClinicalTrials.gov ID: NCT05112601

A Phase I/II Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial involves adults with unresectable or metastatic advanced solid tumors who have progressed on prior treatments or are candidates for pembrolizumab, combining pembrolizumab, which targets the PD-1 receptor to enhance immune response, with a personalized neoantigen peptide vaccine designed to stimulate an individualized immune attack against tumor-associated proteins.

ClinicalTrials.gov ID: NCT05269381

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial involves patients with advanced or metastatic solid tumors expressing Nectin-4, including urothelial carcinoma, triple-negative breast cancer, non-small cell lung cancer, and ovarian cancer, who have exhausted standard therapy options. It evaluates LY4052031, an antibody-drug conjugate that targets Nectin-4 to deliver a topoisomerase I inhibitor, aiming to assess its safety, tolerability, and efficacy in these patients.

ClinicalTrials.gov ID: NCT06465069

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial investigates LNCB74, a B7-H4 targeted antibody-drug conjugate, as monotherapy for adults with advanced, unresectable, or metastatic solid tumors that express B7-H4, aiming to evaluate its safety, tolerability, and efficacy. Participants must have measurable disease, an ECOG performance status of 0-1, and adequate organ function.

ClinicalTrials.gov ID: NCT06774963

A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with unresectable or metastatic solid tumors (including NSCLC, high-grade serous ovarian carcinoma, and uterine serous carcinoma), ECOG 0-1, and at least one accessible lesion for biopsy. Patients receive BMS-986463, a novel investigational antineoplastic agent with an undisclosed mechanism of action, as monotherapy.

ClinicalTrials.gov ID: NCT06476808

An Open-label, Phase 1 Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SMP-3124LP in Adults With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced, recurrent, or metastatic solid tumors (including platinum-resistant ovarian cancer, triple-negative breast cancer, squamous cell carcinoma of the anus or head and neck, non-small cell lung cancer, and uterine serous cancer) who have progressed on all standard therapies, to receive SMP-3124LP, a novel liposomal CHK1 inhibitor given by intravenous infusion. SMP-3124LP targets the DNA damage response pathway and is being assessed for safety, tolerability, and preliminary efficacy.

ClinicalTrials.gov ID: NCT06526819

An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for the KRAS G12D Mutation

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable/metastatic solid tumors harboring KRAS G12D and HLA-C*08:02 (e.g., NSCLC, colorectal, pancreatic, endometrial) after ≥1 prior therapy receive lymphodepletion followed by a single infusion of NT-112, an autologous TCR-engineered T-cell therapy targeting KRAS G12D and CRISPR-edited to disrupt TGF-βRII, with IL-2 support. Single-arm dose escalation assessing safety and preliminary efficacy.

ClinicalTrials.gov ID: NCT06218914